MALIGNANT PLEURAL MESOTHELIOMA
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on deadly lung cancer
Disease control OngoingThis early-stage study is testing whether combining a new form of targeted chest radiation with an immunotherapy drug is safe for people with advanced malignant pleural mesothelioma, a serious cancer often linked to asbestos. The main goal is to find the highest radiation dose th…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 22:55 UTC
-
5-Day radiation blitz tested for deadly lung cancer
Disease control OngoingThis study is testing a shorter, 5-day course of targeted radiation for people with malignant pleural mesothelioma, a serious cancer often linked to asbestos. The treatment is given after surgery or a diagnostic biopsy. The main goal is to see if this faster schedule is safe and …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo treatment tested before surgery for aggressive cancer
Disease control OngoingThis early-stage study is checking if it's safe and practical to give a drug called nivolumab (an immunotherapy) along with standard chemotherapy before surgery for a type of lung cancer called malignant pleural mesothelioma. The main goal is to see if this combination treatment …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC